CHARLES RIVER LABORATORIES INTERNATIONAL, INC. vs INCYTE CORPORATION, two Biotechnology stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where CRL and INCY diverge most: on net margin, CRL reads -4.6% and INCY reads 26.7%; on return on equity, CRL reads -6.3% and INCY reads 25.5%. The rest of the comparable metrics sit closer together. What INCY's price implies is a bet that sits within the historical range (whole-company basis). The bull and bear cases for each are in their full reports below.
| Metric | CRL | INCY |
|---|---|---|
| Price | $232.67 | $119.47 |
| Market cap | $11.4B | $23.9B |
| Sector | Biotechnology | Biotechnology |
| Stage | Mature | Growth |
| Implied growth (priced in) | — | +3.0% |
| P/E | — | 16.9 |
| P/B | 3.87 | 4.24 |
| P/S | 2.83 | 4.45 |
| EV/EBITDA | 26.6 | 12.5 |
| Revenue growth | +0.1% | +21.3% |
| Operating margin | 12.0% | 23.7% |
| Net margin | -4.6% | 26.7% |
| Return on equity | -6.3% | 25.5% |
| Return on assets | -2.4% | 19.5% |
| Return on invested capital | 1.9% | 25.3% |
| FCF yield | 3.4% | 6.3% |
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 1.36 | 3.68 |
| Altman Z (solvency) | 2.32 | 7.62 |
| Piotroski F (quality) | 6 / 9 | 6 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.